Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint
By Nicholas G. Miller
Rezolute said the Food and Drug Administration encouraged it to submit study reports and analysis datasets for its ersodetug drug to treat congenital hyperinsulinism, despite its Phase 3 study missing its primary endpoint.
In a meeting with the FDA, Rezolute presented information to support its belief that the primary endpoint was confounded as a result of behavioral factors.
The company said the unblinded nature of self-monitored glucose, together with perceptions of treatment assignment, may have led to divergent behaviors between treatment groups during the study, which may have impacted the measurement of hypoglycemia.
The company said the FDA acknowledged the challenges posed by those behavioral factors.
The company said that after the FDA reviews study reports and analysis datasets it encouraged Rezolute to submit, it could determine whether there is enough evidence to support the submission of a marketing application or if additional information is required.
The company expects to have an update on the program in the second half of 2026.
Shares were up 2.1% to $2.45 in premarket trading.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
March 24, 2026 08:08 ET (12:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States